Home
News
In Focus
Business
Metro
Nation
World
Sports
Feature
Opinion
View more »Opinion Columns
Wan LixinOpinion deputy editor of Shanghai Daily
Restaurants get off to a quick start thanks to game-changing policies
High service charges on event ticket refunds call for further regulation
Sunday
- Subscribe
Pfizer sees jump in Q2 earnings
Print Edition
PFIZER reported a jump in second-quarter profits yesterday, pointing to growth in key oncology drugs and other medications, although revenues fell more than expected.
Net income in the quarter ending July 2 came in at US$3.1 billion, up 50 percent from the year-ago period. A key factor in the increase was US$816 million in asset impairment costs during the 2016 quarter.
Revenues dipped two percent to US$12.9 billion, in part because of unfavorable foreign exchange rates.
Pfizer pointed to solid growth in such drugs as oncology medications Ibrance and Xtandi, anti-inflammatory drug Xeljanz and blood thinner Eliquis.
These medications have helped make up for smaller sales since drugs like sexual dysfunction drug Viagra lost their patent protection.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
